Date: 2011-06-15
Type of information: Services contract
Compound: Imvamune®
Company: Bavarian Nordic (Denmark) Danish Defence (Denmark)
Therapeutic area: Infectious diseases
Type agreement: Delivery
Action mechanism: smallpox vaccine
Disease: smallpox
Details: Bavarian Nordic has signed a contract with the Danish Defence for the delivery of the company's third generation smallpox vaccine, Imvamune®. Furthermore, Bavarian Nordic has signed a contract with another European NATO country for the delivery of Imvamune®. The vaccines will be delivered in 2011. The size and value of the contracts are undisclosed. Like the U.S. government, which has so far ordered 20 million doses of the vaccine, Imvamune® will form part of these countries' bio-preparedness in the event of a smallpox outbreak due to e.g. an act of terrorism. Although Imvamune® is an unlicensed vaccine, it has been made available for government purchase. Data from more than 10 years of research indicate that IMVAMUNE® has a favorable safety profile and is well tolerated, including in people who are not recommended to receive the traditional smallpox vaccines, such as people with weakened immune systems (e.g. people infected with HIV) or diagnosed with atopic dermatitis (skin allergies).
Financial terms: Financial details were not disclosed.
Latest news:
